Displaying 1 - 20 of 5072
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill Federal Trade Commission - In the Matter of Ferrellgas Partners, L.P., et al.
Federal Trade Commission Act
Clayton Act
FTC Secures Order Resolving Antitrust Concerns with Zillow-Redfin Agreement
Zillow Group/Redfin Corp.
The Federal Trade Commission sued Zillow and Redfin over an unlawful agreement that eliminates Redfin as a competitor in the market for placing advertising of rental housing on internet listing services (ILSs)—the websites that millions of Americans use to find their next rental home. The complaint alleges that in February 2025, Zillow and Redfin entered into an illegal agreement to dismantle Redfin as a competitor in the ILS advertising market for multifamily rental properties.
The FTC joined by five states, today notified the court that it will file a stipulated order that resolves its litigation against Zillow and Redfin and restores competition in the online platforms that renters use to find apartments and property managers use to list rentals.
FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
CareFirst of Maryland, Inc, et al. v. Amgen, et al.
Syngenta and Corteva, FTC v.
The Federal Trade Commission and state partners have filed a complaint in federal court alleging that pesticide manufacturers Syngenta Crop Protection and Corteva, Inc. have used so-called “loyalty” programs to block and restrict generic competition from pesticide markets, leaving farmers to pay elevated prices for crop protection. The complaint seeks to bar Syngenta and Corteva from continuing these programs and from entering into any similar arrangements in the future, and to restore competition to affected markets.
Statement on FTC Win Blocking Loctite, Liquid Nails Construction Adhesive Merger
Henkel, A-Paint
The Federal Trade Commission sued to block Henkel AG & Co. KGaA (Henkel), the manufacturer of the industry-leading Loctite brand construction adhesives, from acquiring Loctite’s main competitor, Liquid Nails. The FTC alleges that the merger would eliminate fierce competition between Loctite and Liquid Nails, leading to higher prices, lower quality, and reduced innovation, all of which would be detrimental to American consumers.
On August 14, 2026, after a seven-day trial, the U.S. District Court for the Southern District of New York granted the FTC’s request for a permanent injunction to block Henkel’s proposed $725 million acquisition of Liquid Nails from private equity firm American Industrial Partners
Statements on the Grant of Early Termination of the FTC’s Investigation of IonQ’s Proposed Acquisition of SkyWater
Statement of Commissioner Mark R. Meador, In the Matter of IonQ, Inc. and SkyWater Technology, Inc.
Statement of Chairman Andrew N. Ferguson In the Matter of IonQ, Inc./ SkyWater Technology, Inc.
FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman
FTC Endorses Ohio Supreme Court Proposal to Weaken ABA’s Law School Accreditation Monopoly
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.
On July 14, 2026, the Federal Trade Commission secured a settlement agreement Caremark Rx LLC and Zinc Health Services LLC (collectively Caremark) .
Caremark has agreed to a settlement agreement that requires the PBM to adopt changes to its business practices to drive down patients’ out-of-pocket costs, increase transparency and ensure community pharmacies are treated fairly.